Centro Hospitalar Lisboa Norte CHLN EPE - Hospital de Santa Maria

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Liver and biliary tract cancer1 trial
• Myeloproliferative neoplasms1 trial

Phase

• Phase 32 trials

Status

• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Kartos Therapeutics, Inc.1 trial
• TransThera Sciences (Nanjing), Inc.1 trial

Running trials

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source

  Contact: John Mei

• Active, not recruiting

  Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

  NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myeloproliferative neoplasms1 recruiting